iShares JPMorgan USD Emerging Markets Bond ETF vs Roivant Sciences Ltd. Common Shares — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.59 (market cap $12.79B), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $24.72B). The key difference: Roivant Sciences Ltd. Common Shares is the larger of the two by market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares JPMorgan USD Emerging Markets Bond ETF for 50 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| EMB | ROIV | |
|---|---|---|
Market Cap | $12.79B | $24.72B |
Volume | 8,552,536 | 6,279,442 |
Sector | Fixed Income | Health |
52-Week High | $97.74 | $41.81 |
52-Week Low | $90.14 | $16.04 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | — | $20.99B |
Signals from Pluang's Aura AI — not financial advice
EMB trades at $90.78, down 0.19% with a bearish technical signal from moving averages. The stock shows mixed momentum with RSI indicators suggesting potential oversold conditions at lower timeframes. Recent corporate actions include scheduled dividend payments through late 2026, though key valuation and profitability metrics remain unavailable for analysis.
The outlook remains cautious with technical indicators favoring bearish momentum. Investment appeal may center on future dividend income given the lack of current fundamental data. Primary risks include market volatility and the absence of transparent financial metrics for proper valuation assessment.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →